The main purpose of this study was to prepare binary lipids-based nanostructured lipid carriers to improve the oral bioavailability of silymarin, a poorly water-soluble liver protectant. Silymarin-loaded nanostructured lipid carriers were prepared by the method of high-pressure homogenization with glycerol distearates (Precirol ATO-5) and oleic acid as the solid and liquid lipids, respectively, and lecithin (Lipoid E 100) and Tween-80 as the emulsifiers. The silymarin-nanostructured lipid carrier prepared under optimum conditions was spherical in shape with mean particle size of ∼78.87 nm, entrapment efficiency of 87.55%, loading capacity of 8.32%, and zeta potential of −65.3 mV, respectively. In vitro release of silymarin-nanostructured lipid carriers was very limited even after 12 h, while in vitro lipolysis showed fast digestion of nanostructured lipid carriers within 1 h. Relative oral bioavailability of silymarin-nanostructured lipid carriers in Beagle dogs was 2.54- and 3.10-fold that of marketed Legalon® and silymarin solid dispersion pellets, respectively. It was concluded that nanostructured lipid carriers were potential drug delivery systems to improve the bioavailability of silymarin. Other than improved dissolution, alternative mechanisms such as facilitated absorption as well as lymphatic transport may contribute to bioavailability enhancement.
WenZDumasTESchrieberSJ. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos2008; 36: 65–72.
2.
LuCLuYChenJ. Synchronized and sustained release of multiple components in silymarin from erodible glyceryl monostearate matrix system. Eur J Pharm Biopharm2007; 66: 210–219.
3.
Abenavoli L, Milic N and Capasso F. Anti-oxidant therapy in non-alcoholic fatty liver disease: the role of silymarin. Endocrine 2012; 42: 754–755.
4.
FriedMWNavarroVJAfdhalN. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis c unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA2012; 308: 274–282.
5.
LuperS. A review of plants used in the treatment of liver disease: Part 1. Altern Med Rev1998; 3: 410–421.
6.
LoguercioCFestiD. Silybin and the liver: from basic research to clinical practice. World J Gastroenterol2011; 17: 2288–2301.
7.
Rainone F. Milk thistle. Am Fam Physician 2005; 72: 1285–1288.
8.
Pepping J. Milk thistle: Silybum marianum. Am J Health Syst Pharm 1999; 56: 1195–1197.
9.
WuWWangYQueL. Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur J Pharm Biopharm2006; 63: 288–294.
10.
LiXYuanQHuangY. Development of silymarin self-microemulsifying drug delivery system with enhanced oral bioavailability. AAPS PharmSciTech2010; 11: 672–678.
11.
WooJSKimTSParkJH. Formulation and biopharmaceutical evaluation of silymarin using smedds. Arch Pharm Res2007; 30: 82–89.
12.
CaoXFuMWangL. Oral bioavailability of silymarin formulated as a novel 3-day delivery system based on porous silica nanoparticles. Acta Biomater2012; 8: 2104–2112.
13.
SunNZhangXLuY. In vitro evaluation and pharmacokinetics in dogs of solid dispersion pellets containing Silybum marianum extract prepared by fluid-bed coating. Planta Med2008; 74: 126–132.
Yan-YuXYun-MeiSZhi-PengC. Preparation of silymarin proliposome: a new way to increase oral bioavailability of silymarin in beagle dogs. Int J Pharm2006; 319: 162–168.
16.
YanyuXYunmeiSZhipengC. The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats. Int J Pharm2006; 307: 77–82.
17.
HeJHouSLuW. Preparation, pharmacokinetics and body distribution of silymarin-loaded solid lipid nanoparticles after oral administration. J Biomed Nanotech2007; 3: 195–202.
18.
PorterCJTrevaskisNLCharmanWN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov2007; 6: 231–248.
19.
JenningVThunemannAFGohlaSH. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm2000; 199: 167–177.
20.
QiJLuYWuW. Absorption, disposition and pharmacokinetics of solid lipid nanoparticles. Curr Drug Metab2012; 13: 418–428.
21.
MullerRHRadtkeMWissingSA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev2002; 54(Suppl 1): S131–S155.
22.
MuchowMMaincentPMullerRH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm2008; 34: 1394–1405.
23.
DasSChaudhuryA. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech2011; 12: 62–76.
24.
ZhuangCYLiNWangM. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm2010; 394: 179–185.
25.
ZhengDDaiWZhangD. In vivo studies on the oridonin-loaded nanostructured lipid carriers. Drug Deliv2012; 19: 286–291.
26.
MuchowMMaincentPMullerRH. Production and characterization of testosterone undecanoate-loaded NLC for oral bioavailability enhancement. Drug Dev Ind Pharm2011; 37: 8–14.
27.
MullerRHRungeSARavelliV. Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm2008; 68: 535–544.
28.
MullerRHMaderKGohlaS. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm2000; 50: 161–177.
29.
Mehnert W and Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001; 47: 165--196.
30.
SunNWeiXWuB. Enhanced dissolution of silymarin/polyvinylpyrrolidone solid dispersion pellets prepared by a one-step fluid-bed coating technique. Powder Technol2008; 182: 72–80.
31.
SchwarzCMehnertW. Solid lipid nanoparticles (SLN) for controlled drug delivery. Ii. Drug incorporation and physicochemical characterization. J Microencapsul1999; 16: 205–213.
32.
PorterCJCharmanWN. In vitro assessment of oral lipid based formulations. Adv Drug Deliv Rev2001; 50(Suppl. 1): S127–S147.
33.
PorterCJKaukonenAMBoydBJ. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm Res2004; 21: 1405–1412.
34.
JiaLZhangDLiZ. Nanostructured lipid carriers for parenteral delivery of silybin: biodistribution and pharmacokinetic studies. Colloids Surf B Biointerf2010; 80: 213–218.
35.
MullerRHPetersenRDHommossA. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev2007; 59: 522–530.
36.
LarsenATSassenePMullertzA. In vitro lipolysis models as a tool for the characterization of oral lipid and surfactant based drug delivery systems. Int J Pharm2011; 417: 245–255.
37.
MacGregorKJEmbletonJKLacyJE. Influence of lipolysis on drug absorption from the gastro-intestinal tract. Adv Drug Deliver Rev1997; 25: 33–46.
38.
DahanAHoffmanA. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release2008; 129: 1–10.
39.
CuineJFMcEvoyCLCharmanWN. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. J Pharm Sci2008; 97: 995–1012.
40.
TrevaskisNLCharmanWNPorterCJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev2008; 60: 702–716.
